Form 4: Neogenomics CFO Jeffrey Scott Sherman Reports Stock and Options Holdings

Chief Financial Officer Jeffrey Scott Sherman reports holdings in Neogenomics stock, restricted stock units, and stock options.

Summary

• Jeffrey Scott Sherman, CFO of Neogenomics Inc., filed a Form 4 detailing his beneficial ownership of company securities.
• As of January 14, 2025, Sherman directly owns 123,754 shares of Neogenomics common stock.
• He also holds various restricted stock units (RSUs) and stock options with different vesting schedules and exercise prices.
• These include 59,382 RSUs granted on January 14, 2025, vesting on April 13, 2026.
• Sherman also holds options to buy 249,169 shares at $11.62 (granted December 5, 2022, vesting over four years), 73,016 shares at $19.65 (granted May 11, 2023, vesting over three years), and 77,913 shares at $16.45 (granted February 23, 2024, vesting over three years).
• Additionally, he holds performance stock units (PSUs) granted on May 11, 2023 (39,016 shares at target, up to 58,524 at maximum) and February 23, 2024 (46,606 shares at target, up to 69,910 at maximum), vesting based on share and revenue growth goals.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of securities ownership. It doesn't contain overtly positive or negative information, but the fact that the CFO holds a significant amount of company stock and options is generally a neutral to slightly positive signal.

Positives

• The reporting person's continued holding of company stock and options suggests confidence in the company's future performance.
• The vesting schedules of the stock options and RSUs incentivize long-term commitment from the CFO.

Industry Context

Form 4 filings are standard practice and provide transparency into the holdings of company insiders, allowing investors to gauge management's alignment with shareholder interests. It is common for executives to hold a mix of stock, options, and RSUs as part of their compensation packages.

Comparison to Industry Standards

• Executive compensation packages in the diagnostics and healthcare industry typically include a mix of base salary, stock options, restricted stock units, and performance-based bonuses.
• The vesting schedules and performance criteria outlined in the document are fairly standard for incentivizing long-term growth and aligning executive interests with shareholder value.
• Comparing the size of Sherman's holdings and option grants to those of CFOs at comparable companies (e.g., Exact Sciences, Guardant Health) would provide a more detailed assessment of the competitiveness of his compensation package.

Stakeholder Impact

• Shareholders can use this information to understand the CFO's stake in the company's success.
• Employees may view the CFO's holdings as a sign of confidence in the company's future.
• The filing has minimal direct impact on customers, suppliers, or creditors.

Key Dates